Jonathan Alspaugh

Chief Financial Officer, Aeglea BioTherapeutics.

Companies

Aeglea BioTherapeuticsPresident Jun 30, 2023 to Jun 30, 2023¹
Aeglea BioTherapeuticsChief financial officer Jul 8, 2021 to Jun 30, 2023²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Aeglea BioTherapeutics SYRE165,372 shares³$14.2M at $85.57Mar 11, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 11, 2022Bought 75,000 shares at $2.08 of Aeglea BioTherapeutics³
Dec 9, 2021Bought 50,000 shares at $3.72 of Aeglea BioTherapeutics⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAeglea BioTherapeutics, President
2
SEC EDGARAeglea BioTherapeutics, Chief financial officer
3
SEC EDGARAeglea BioTherapeutics shares after the filing of Mar 11, 2022
4
SEC EDGARForm 4 filed Dec 13, 2021